Telomir Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Feb 4, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 4, 2025
TELO$0.57-17.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
BALANCE SHEETS
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash | $1,266,131 | $1,231 |
| Deferred offering costs | - | 303,281 |
| Prepaid expenses | 57,874 | 713 |
| Due from related parties | - | 130,000 |
| Total current assets | 1,324,005 | 435,225 |
| Deferred financing costs | - | 4,338,543 |
| Total assets | $1,324,005 | $4,773,768 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Trade accounts payable and accrued liabilities | $587,536 | $707,187 |
| Due to related parties | 93,432 | 527,377 |
| Related party line of credit | - | 101,000 |
| Total current liabilities | 680,968 | 1,335,564 |
| Total liabilities | 680,968 | 1,335,564 |
| Stockholders’ Equity | ||
| Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding. | - | - |
| Common Stock, no par value; 300,000,000 shares authorized, 29,762,671 and 28,609,814 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively. | - | - |
| Additional paid-in capital | 31,239,895 | 17,502,346 |
| Accumulated deficit | (30,596,858) | (14,064,142) |
| Total stockholders’ equity | 643,037 | 3,438,204 |
| Total liabilities and stockholders’ equity | $1,324,005 | $4,773,768 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.